Study of Multiple Myeloma Occurrence in Patients With 5%-10% Bone Marrow Plasma Cells: A Case Series Regarding Revised IMWG Diagnostic Criteria

Authors

  • Hasan Jalaeikhoo AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran.
  • Manoutchehr Keyhani Hematology and Oncology Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran. Address: Keshavarz Blvd., Imam Khomeini Hospital Complex, Vali-Asr hospital, Tehran, Iran.
  • Mohammad Zokaasadi AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran.
  • Mohsen Rajaeinejad AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran.
  • Morteza Sharifzadeh AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran.
Abstract:

Introduction: Utilizing lower limit of bone marrow plasma cells (BMPCs) is the main existing criterion for diagnosis of multiple myeloma (MM). According to the revised international myeloma working group (IMWG) diagnostic criteria, the value of 10% is agreed among experts as the cutoff level for diagnosis. Symptomatic patients with BMPC above this value are identified as definite cases of MM. However, there are MM patients who have BMPC of less than 10%. Considering abovementioned cutoff could delay the diagnosis which in turn results in adverse effects in patients’ clinical course. Case presentation: This study represented data of consecutive patients with 5% to 10% BMPC at our center from 2004 to 2013. MM existed among patients, as expected. This series provides a quantitative approximation of MM prevalence in these cases. Conclusion: The reported patients’ status demonstrates the limitations of the abovementioned cutoff criterion in myeloma diagnosis, and emphasizes the importance of employing further diagnostic procedures in patients with marginal amounts of BMPC and high clinical suspicion. It has been shown that supplementary examination is especially required for two subgroups of patients with certain clinical and laboratory characteristics. The detail of the cases and results are thoroughly explained in the paper. 

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma

Diagnosis of multiple myeloma (MM) is based on diagnostic criteria which include clonal plasma cell (PC) percentage, quantity of monoclonal protein and presence of CRAB symptoms (hypercalcemia, renal insufficiency, anemia, bone lesion). According to the previously adopted world health organization (WHO) 2008 criteria, the presence of clonal plasma cells is considered as key evidence of clonal p...

full text

In vitro Effect of Pomalidomide on Bone Marrow Mononuclear Cells from Multiple Myeloma Patients

Background: Many features of anticancer drugs, including cytotoxicity and/or cytokine induction, are studied using cell lines orhuman blood leukocytes. However, in a disease such as multiple myeloma, most cancerous cells are resided within bone marrowmononuclear cells. In the present study, we investigated the effect of pomalidomide on apoptosis and IL-2 production of bonemarrow mononuclear cel...

full text

33 CASES OF MULTIPLE MYELOMA WITH MASSIVE BONE DESTRUCTION: REPORT OF A 10-YEAR STUDY IN NORTHEASTERN IRAN

The author studied 133, 856 admissions over a ten-year period and found 138 cases of primary tumors of bone. Of these only 33 were multiple myeloma. Incidence, clinical manifestation, age, sex and etiology are reported, and the effect of four different chemotherapy regimens are evaluated.

full text

Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities.

Benign monoclonal protein was first described by Waldenstrm in 1960 after abnormal narrow hypergammaglobulinemia bands were noted in the serum of healthy individuals on serum protein electrophoresis.[1] In 1978, Kyle coined the term “monoclonal gammopathy of undetermined significance (MGUS)” after observing that asymptomatic patients with monoclonal protein have a higher risk of developing mult...

full text

Frequency of FLT3 ITD and FLT3 TKD Mutations in Multiple Myeloma Patients (A Case Control Study)

Background and Aims: Multiple myeloma is a malignant proliferation of plasma cells derived from a single clone. The tumor, its products and the host response lead to organ damages. Some factors that are responsible in its pathogenesis are recognized. As FMS like Tyrosine Kinase 3 receptor (FLT3) mutation has been proved as a determining factor in leukemic patients the goal of this study was to ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue 3

pages  30- 35

publication date 2018-07

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023